Article
Targeting synthetic lethality between non-homologous end joining and radiation in very high-risk SHH medulloblastoma
2024-11-12
Abstract excerpt
<h4>Summary</h4> Specific and biologically informed treatments for medulloblastoma, especially the highly lethal TP53 mutant SHH subgroup, remain elusive, where radiotherapy is the primary treatment option. Applying genome-wide CRISPR-Cas9 screening in combination with lethal doses of radiotherapy, we identified the main driver of radiation resistance in SHH medulloblastoma is loss of p53. A negative selection C...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- bc4aee5f-fc87-573b-a18d-2a204a250fca
- DOI
- 10.1101/2024.11.11.622104
